BostonGene

Join us this week at #SITC24, where we will present six studies showcasing advancements in AI-powered tumor microenvironment profiling, genomic analysis, biomarker identification, immune-related adverse event prediction and novel drug targeting, paving the way for precision oncology. Learn more: https://lnkd.in/g2mfp3yJ

Meet us next week at #PathVisions24! “Pathology Visions offers a dynamic platform for driving progress in digital pathology. The conference brings together diverse experts from around the world. I’m excited to moderate the discussion on advancing regulatory science. Collaborative efforts between industry, academia, and regulatory bodies are essential to accelerate digital pathology adoption in the U.S. This conference is a valuable opportunity to share insights, explore innovative solutions and shape the future of pathology for better patient care.” - Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene. Learn more: https://lnkd.in/ebZSTREf

Join us this week at the APM Annual Conference 2024! During the event, Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene, will participate in a panel session highlighting scalable solutions for enhancing access to precision medicine and reducing care disparities through guidelines and network-based approaches. “At APM 2024, we’re excited to explore practical solutions for expanding precision medicine’s reach in cancer care. This session will highlight how network-based approaches can improve diagnostic access in underserved areas, reducing treatment disparities and advancing precision medicine for all patients.” - Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene Learn more: https://lnkd.in/e6BnPfTZ

The BostonGene team had an outstanding experience at the 31st Prostate Cancer Foundation scientific retreat in Carlsbad, CA. We were thrilled to introduce our solutions for patients, including our immune system profiling platform to this phenomenal group of physicians, scientists, drug developers, and philanthropists that are striving to produce better outcomes for prostate cancer patients.

Join us for the @sitcancer Annual Meeting! Be part of the #SITC24 experience!

Join us this week in Barcelona for #ENA2024! During the event, Joe Lennerz, MD, PhD, Chief Scientific Officer at BostonGene will deliver a presentation discussing the crucial role of regulatory oversight in shaping laboratory-developed tests, highlighting challenges and solutions to improve accuracy, reliability and patient safety.  “We are eager to share our insights on the regulatory landscape and the importance of biomarkers in shaping the future of cancer therapeutics. The presentation will underscore the need for robust regulatory frameworks to support innovation, speed up drug discovery and ultimately enhance patient outcomes in this rapidly evolving field.” - Joe Lennerz Learn more: https://lnkd.in/gkbBeNg2

We're pleased to announce that Fujita Health University Haneda Clinic will now offer genomic profile testing for cancer patients using the BostonGene Tumor Portrait™ test. By predicting the efficacy of immune checkpoint inhibitors, the Tumor Portrait™ supports more effective treatment selection, reducing unnecessary interventions and side effects. This collaboration marks a significant step forward in precision medicine, ensuring that more patients can benefit from tailored therapies that improve outcomes and enhance quality of life. Read more: https://lnkd.in/exaRxNFb

Join us this week at #AVBCC2024, where Mark Hiatt, MD, MBA, MS, Senior Vice President of Market Access and Strategy at BostonGene and Anna Ogloblina, PhD, Senior Director of Market Access and Product Management at BostonGene, will participate in two panels to provide insights on leveraging multiomic data and advanced screening to enhance value-based cancer care, with a focus on improving patient outcomes and cost-effectiveness. Learn more: https://lnkd.in/e3CPegpA

We are excited to collaborate with Sarah Cannon Research Institute (SCRI) to integrate innovative molecular testing and informatics platforms into the clinical decision-making processes at SCRI's Phase 1 clinics. This collaboration also aims to validate novel biomarkers using BostonGene’s AI-powered multiomics platform in real-world cancer populations, further advancing the potential for personalized oncology care. Read more: https://lnkd.in/gAtv8649 "By integrating BostonGene's advanced molecular profiling into our phase 1 clinical workflows, physicians are poised to significantly enhance our ability to make precise, data-driven treatment decisions. We look forward to the impact we can make in advancing personalized oncology care through our strategic collaboration. " - Andrew McKenzie, PhD, Vice President of Personalized Medicine at SCRI and Scientific Director at Genospace. "We are thrilled to collaborate with SCRI, integrating our AI-driven multi-omics platform into select community oncology practices. This collaboration will enable us to personalize cancer treatment more effectively and expedite biomarker discovery and validation, ultimately shifting the standard of care and improving patient outcomes." - Nathan Fowler, MD, Chief Medical Officer at BostonGene.

You always hear about Next-Generation Sequencing (NGS), but what is it really? Why should you use it and when is it most beneficial? In this episode of #HealthcareUnfiltered, Chadi Nabhan, MD, MBA,FACP, sits down with Joe Lennerz, Chief Scientific Officer at BostonGene, to break down the essentials of NGS. They explore how this powerful technology works, as well as its advantages and potential pitfalls. Watch now: https://lnkd.in/eyTsRzFQ